Department of Neurology, The Affiliated Hospital of Guizhou Medical University, Guizhou 550004, China.
Neurosurgery Department of Chongqing University, Three Gorges Hospital, Chongqing 400010, China.
Oxid Med Cell Longev. 2022 Oct 27;2022:3858314. doi: 10.1155/2022/3858314. eCollection 2022.
Ischemic stroke exhibits high morbidity, disability, and mortality, and treatments for ischemic stroke are limited despite intensive research. The potent neuroprotective benefits of Epimedium against ischemic stroke have gained lots of interest. Nevertheless, systematic research on the direct role and mechanisms of Epimedium in ischemic stroke is still lacking. Network pharmacology analysis coupled with experimental verification was utilized to systematically evaluate the potential pharmacological mechanism of Epimedium against ischemic stroke. The TCMSP database was used to mine the bioactive ingredients and Epimedium's targets. The DrugBank, OMIM, and GeneCards databases were employed to identify potential targets of ischemic stroke. GO and KEGG pathway analyses were also carried out. The interaction between active components and hub targets was confirmed via molecular docking. An experimental ischemic stroke model was used to evaluate the possible therapeutic mechanism of Epimedium. As a result, 23 bioactive compounds of Epimedium were selected, and 30 hub targets of Epimedium in its function against ischemic stroke were identified, and molecular docking results demonstrated good binding. The IL-17 signaling pathway was revealed as a potentially significant pathway, with the NF-B and MAPK/ERK signaling pathways being involved. Furthermore, in vivo experiments demonstrated that Epimedium treatment could improve neurological function and reduce infarct volume. Additionally, Epimedium reduced the activation of microglia and astrocytes in both the ischemic penumbra of the hippocampus and cerebral cortex following ischemic stroke. Western blot and RT-qPCR analyses demonstrated that Epimedium not only depressed the expression of IL-1, TNF-, IL-6, and IL-4 but also inhibited the NF-B and MAPK/ERK signaling pathways. This study applied network pharmacology and in vivo experiment to explore possible mechanism of Epimedium's role against ischemic stroke, which provides insight into the treatment of ischemic stroke.
缺血性脑卒中具有高发病率、高致残率和高死亡率的特点,尽管进行了深入研究,但缺血性脑卒中的治疗方法仍然有限。淫羊藿具有很强的神经保护作用,因此针对缺血性脑卒中的治疗作用引起了广泛关注。然而,系统研究淫羊藿在缺血性脑卒中中的直接作用和机制仍然缺乏。本研究采用网络药理学分析结合实验验证的方法,系统评价淫羊藿防治缺血性脑卒中的潜在药理机制。通过 TCMSP 数据库挖掘淫羊藿的生物活性成分和作用靶点,利用 DrugBank、OMIM 和 GeneCards 数据库筛选缺血性脑卒中的潜在靶点,进行 GO 和 KEGG 通路分析,采用分子对接验证活性成分与关键靶点的相互作用,通过建立缺血性脑卒中模型实验评估淫羊藿的可能治疗机制。结果表明,从淫羊藿中筛选得到 23 个活性成分,鉴定出 30 个淫羊藿防治缺血性脑卒中的关键靶点,分子对接结果显示两者结合良好。IL-17 信号通路可能是淫羊藿发挥作用的关键通路,涉及 NF-B 和 MAPK/ERK 信号通路。进一步的体内实验表明,淫羊藿治疗可改善缺血性脑卒中后大鼠的神经功能,减小脑梗死体积,减轻缺血半暗带区海马和皮质内小胶质细胞和星形胶质细胞的激活。Western blot 和 RT-qPCR 结果表明,淫羊藿不仅可以下调 IL-1、TNF-、IL-6 和 IL-4 的表达,还可以抑制 NF-B 和 MAPK/ERK 信号通路。本研究采用网络药理学和体内实验相结合的方法,探讨了淫羊藿防治缺血性脑卒中的作用机制,为缺血性脑卒中的治疗提供了新的思路。